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Abstract.  TA3/Ha murine mammary carcinoma cells 
grow in suspension, do not adhere to extracellular 
matrix molecules, but do adhere to hepatocytes and 
form liver metastases upon intraportal injection. Re- 
cently we showed that the integrin ottfl4 on the TA3/Ha 
cells is involved in adhesion to hepatocytes. However, 
despite high cell surface levels of o~6B4, TA3/Ha cells 
do not adhere to the ot6~4 ligands laminin and kalinin. 
Here we show that this is due to the mucin epiglyca- 
nin that is highly expressed on TA3/Ha cells.  Some 
monoclonal antibodies generated against epiglycanin 
induced capping of most of the epiglycanin molecules. 
TA3/Ha cells treated with these mAb did adhere to 
laminin and kalinin, and an epithelial monolayer was 
formed on kalinin, with ot6~4 localized in HDl-contain- 
ing hemidesmosome-like structures and E-cadherin at 
the cell-cell contact sites.  Similar results were obtained 
after treatment of TA3/Ha cells with O-sialoglycopro- 
tein endopeptidase which removes all epiglycanin. In 
addition, the enzyme induced E-cadherin-mediated 
cell-cell aggregation. Both treatments also enhanced 
the adhesion to hepatocytes, but given the potent anti- 
adhesive effect of epiglycanin it is remarkable that 
nontreated TA3/Ha cells adhere to hepatocytes at all. 
We found that during this interaction, epiglycanin was 
redistributed. We conclude that epiglycanin can com- 
pletely prevent both intercellular and matrix adhesion, 
but that this effect can be overcome in certain intercel- 
lular interactions because of the induced redistribution 
of the mucin. 
TRINGENT regulation of cell adhesion is  crucial  for 
normal development and maintenance of tissue archi- 
tecture, as well as for the control of processes that in- 
volve migration of cells (Edelman and Crossin, 1991; Hynes 
and  Lander,  1992;  Hyndes,  1992).  This  regulation  is 
achieved by changes in the expression of a large variety of 
adhesion molecules and splice variants, and in addition by 
modulation  of  the  avidity  of these  molecules  for  their 
ligands, due to altered molecular conformation or to changes 
in surface distribution. In addition, adhesion can be impeded 
by molecules that mask binding sites. For surface molecules, 
this was first shown for embryonic neuronal cell adhesion 
molecule  (NCAM), ~ which  contains  a  large  amount  of 
negatively charged sialic acid. This hinders both the adhe- 
sion mediated by NCAM  itself and interactions between 
other  surface  molecules  (Hoffman and  Edelman,  1983; 
Rutishauser et al., 1988).  More recently, it was shown that 
Address all correspondence to E. Roos, Division of Cell Biology (HI), The 
Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The 
Netherlands. Ph: (31) 20-512-1931.  Fax:  (31) 20-512-1944. 
1. Abbreviation used in this paper:  NCAM, neuronal cell adhesion mol- 
ecule. 
cell  surface  mucins  and  proteoglycans can  have  similar 
effects and cause substantial reduction of cell adhesion (Lig- 
tenberg et al., 1992; Hilkens et al., 1992; Manjunath et al., 
1993;  Vleminckx et al.  1994). 
We have studied the interaction between carcinoma cells 
and hepatocytes, which is likely to play a major role in the 
formation of liver metastases (Roos, 1991). One of the cell 
lines studied was the TA3/Ha murine mammary carcinoma. 
TA3/Ha cells grow as single cells in suspension and do not 
adhere  to  several  different extracellular  matrix  proteins 
(Kemperman et al., 1994). Yet, the cells do adhere to hepa- 
tocytes and form metastases in the liver after intraportal in- 
jection, and also in the liver the cells interact closely with 
hepatocytes (Roos et al., 1978).  TA3/Ha cells express very 
low levels of fl~ integrins, but do express high levels of the 
integrin ot~4.  We have demonstrated that otd~4 is involved 
in  the  interaction  with  hepatocytes  (Kemperman  et  al., 
1993). This integrin is known to bind to laminin (laminin-1) 
and kalinin (laminin-5) (Lee et al.,  1992;  Niessen et al., 
1994; for the new nomenclature for the laminins see Burge- 
son et al., 1994), but these proteins appear not to be present 
at substantial amounts in hepatocyte cultures and the protein 
on the hepatocyte surface to which the TA3/Ha cells bind 
therefore remains to be identified. The lack of adhesion of 
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explained by the low levels  of/~1  integrins.  However,  we 
were surprised to find that the cells also do not adhere to the 
~s/34 ligands laminin (Kemperman, et al.,  1994)  and kali- 
nin, as shown here. 
TA3/Ha  cells  express  high  levels  of a  mucin,  termed 
epiglycanin. This mucin has been suggested to mask surface 
molecules, in particular H2 histocompatibility antigens, and 
thus, to be responsible for the ability of the cells to grow in 
aUogeneic mouse strains, despite the expression of the H2 
antigens (Codington et ai., 1978; Miller et al., 1982).  This 
is in line with findings by others that surface mucins can in- 
terfere with host immune responses (Sherblom and Moody, 
1986; Bharathan et al., 1990; Van de Wiel-van Kemenade et 
al.,  1993).  Epiglycanin expression has so far not been as- 
sociated with the lack of adhesive capacity of the TA3/Ha 
ceils. We show here that these cells express an intact E-cad- 
herin/catenin complex, despite their lack of intercellular ad- 
hesion. Upon capping of epiglycanin, the cells formed an 
epithelial monolayer on kalinin with c~6/34 in hemidesmo- 
some-like structures and E-cadherin concentrated in inter- 
cellular contact areas. After complete removal of epiglyca- 
nin,  the  cells were  also  capable  of E-cadherin-mediated 
aggregation in suspension. This demonstrates that epiglyca- 
nin is extremely potent in the prevention of cell adhesion. 
However,  we also show that this effect can be overcome in 
certain interactions, e.g., between TA3/Ha cells and hepato- 
cytes, apparently because epiglycanin is redistributed. 
Materials and Methods 
Cells, Antibodies, and Extracellular Matrix Proteins 
Mouse TA3/Ha mammary carcinoma cells were maintained as described 
(Hauschka et ai., 1971). Metastasis formation in vivo and adhesion to hepa- 
tocyte cultures in vitro by these cells have been described (Roos et al., 
1978). 
Mouse and rat fibronectin were from Telios Pharmaceuticals Inc. (San 
Deigo, CA) and GIBCO BRL (Gaithersburg, MD),  respectively. Mouse 
laminin was from Boehringer Mannheim GmbH (Mannheim, Germany), 
and mouse type I and type IV collagen were from Sigma Chemical Co. (St. 
Louis, MO) and GIBCO BRL, respectively. Kalinin-rich matrix was pre- 
pared  as  described by  Sonnenberg et  al.  (1993).  Purified epiglycanin 
(Codington et ai.,  1979)  was kindly supplied by Dr. Codington. 
The rat mAb GoH3 against mouse ct6 was described by Sonnenberg et 
al. (1988).  FITC-labeled GoH3 was prepared according to the instructions 
of the supplier of the fluorescent dye (Molecular Probes, Eugene, OR). 
Mouse mAb 121  reacting with mouse HD1  was kindly supplied by Dr. 
Owaribe (Hieda et al.,  1992).  Polyclonai antibodies and mAb DECMA-1 
against mouse E-cadherin were kindly supplied by Dr. Kemler (Vestweber 
and Kemler, 1984).  Rat mAb KM 201 directed against mouse CD44 was 
kindly supplied by Dr. Kincade (Miyake et al., 1990).  Rabbit antiserum 67 
reacting with mouse 84 was obtained as follows. A eDNA fragment encod- 
ing the complete cytoplasmic domain of the human 84 integrin subunit was 
cloned into pQE-11  (Qiagen Inc.,  Chatsworth,  CA).  Production of the 
6 xHis-B4 fusion protein by transformed bacteria was induced according to 
the instructions of the supplier. Bacteria were lysed in 1% Triton X-100, and 
centrifuged at 3,000 g for 10 rain. The pellet was resuspended in Laemmli 
sample buffer and proteins were separated by 7 % reduced SDS-PAGE. The 
gel was stained in 0.02 % Coomassie brilliant blue, and the band containing 
the 120-kD  fusion protein was excised, crushed, and used to immunize a 
rabbit. Subsequent booster immunizations were given at 4-wk intervals. 
Hamster hybridomas producing mAb against TA3/Ha cells were gener- 
ated by fusion of mouse Sp2/0 cells with spleen cells of Armenian hamsters 
immunized with TA3/Ha plasma membranes, using standard procedures 
(Bright et al., 1990). The immunization schedule was as follows. Hamsters 
were injected subcutaneously with 400/~g TA3/Ha plasma membrane pro- 
tein in Freund's complete adjuvant, followed by two booster injections in 
Freund's incomplete adjuvant after 2 and 4 wk. A final booster injection was 
given i.v. without adjuvant after eight weeks. 4 d later the fusion was per- 
formed.  Fab fragments were prepared as described (Kemperman et al., 
1993). 
Electrophoresis and Immunoblotting 
Proteins were solubilized in Laemmli sample buffer, separated by reduced 
SDS-PAGE, and subsequently electrophoreticaily transferred to a nitrocel- 
lulose membrane using the Tris-glycine buffer system. To visualize protein 
transfer, blots were reversibly stained with 0.4% Ponceau-S in 3 % trichloro- 
acetic acid. All subsequent incubations were done on a rotary platform at 
20°C. Blots were treated for 1 h in block buffer (1% low fat milk powder, 
0.1% Triton 31:-100 in PBS), and then incubated with first antibodies in block 
buffer for 1 h. Next, biotin-conjugated second antibodies were applied, fol- 
lowed by streptavidin-alkaiine  phosphatase in block buffer. After each incu- 
bation, blots were washed three times with block buffer, and also once with 
PBS before the color reaction. The alkaline phosphatase was detected by 
incubating the blot in suhstrate buffer (100 mM Tris, pH 9.5, 100 mM NaCl, 
and 5 mM MgCI2) containing nitroblue tetrazolium and 5-bromo-4-chloro- 
3-indolyl-phosphate (both from Pierce Chemical Co., Rockford, IL). 
Hepatocyte Isolation and Culture 
Rat hepatocytes were isolated as described previously (Roos and Van de 
Pavert, 1982). Cells were seeded in 96-well Primaria microtiter plates (Fal- 
con  Labware,  Oxnard,  CA)  at  4  ×  104  cells  per  well  in  DME  sup- 
plemented with 5/zg/ml bovine insulin, 2 mM glutamine, 20 mM Hepes. 
Before seeding, wells had been coated with 50 #l of a I0/~g/mi rat fibronec- 
tin solution. 2 h after seeding, the hepatocytes were washed twice and cul- 
tured overnight in the same medium containing 10%  fetal calf serum. 
In Vitro Adhesion to Hepatocytes and Extracellular 
Matrix Molecules 
After overnight culture, hepatocytes were washed twice with DME. Adhe- 
sion of tumor cells to  hepatucytes was quantitated as described (Mid- 
delkoop et al.,  1985).  Briefly,  3  ×  104 51Cr-labeled  (Amersham Interna- 
tional, Amersham, UK) TA3/Ha cells were preincubated in 15/~1 DME with 
or without antibodies for 30 min at 37°C.  Subsequently, the cells were 
added to a  microtiter well containing hepatocytes in 50  #1  DME.  The 
nonadherent cells were washed away, cultures were lysed in  100/~1  1 N 
NaOH, and radioactivity was counted. 
For adhesion to extracellular matrix molecules, microtiter plates (96- 
well round-bottom; Greiner GmBH, Trickenhausen, Germany) were coated 
for 2 h at 37°C with 50 ~l/well of a 10 #g/ml extracellular matrix protein 
solution in PBS, washed with DME, and incubated with 100 td of  0.5 % BSA 
in DME for 30 rain at 20°C to block remaining protein binding sites. Adhe- 
sion of TA3/Ha cells to the various extracellular components was assayed 
similarly as described above for the adhesion to hepatocytes. 
Immunoprecipitation 
TA3/Ha cells (2  ×  106 per precipitation) were surface-labeled with 125I 
(Amersham International) using the lactoperoxidase method, or metaboli- 
cally  for 4  h  with  [35S]methionine/cysteine  (Amersham International). 
Cells were lysed in lysis buffer (1% Triton X-100,  100 mM NaCI, 4 mM 
EDTA and 25 mM "Iris, pH 7.5)  for 1 h at 4°C. Lysates were cleared by 
spinning at 14,000 g for 10 rain. Rabbit antibodies were precipitated with 
protein A-Sepharose beads overnight, added to the lysate and centrifuged 
after 2 h. Rat, mouse, and hamster monoclonal antibodies were precipitated 
with protein A-Sepharose beads that had been preineubated with rabbit 
anti-rat, anti-mouse, or anti-hamster IgG antibodies, respectively (all from 
Nordic, Tilburg, The Netherlands). 2 ~1 from polyclonal sera or 50 t~l by- 
bridoma supernatant was used per precipitation. The immunoprecipitates 
were boiled in Laemmli sample buffer and analyzed by reduced SDS-PAGE. 
O-Sialoglycoprotein Endopeptidase, Neuraminidase, 
and O-Glycosidase Digestions 
O-siaioglycoprotein endopeptidase was purchased from Cedarlane Labora- 
tories (Ontario, Canada). TA3/Ha cells (5  ×  106/ml) were incubated with 
the glycoprotease (12 p.g/ml) in PBS without Mg  2+ and Ca  2+ at 37°C for 
45 rain. If cells were to be used for aggregation assays, the digestion was 
performed in PBS containing 1 mM Mg  2+ and Ca  2+. 
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Figure 1.  Characterization of anti-epiglycanin mAb. (.4) Western blotting. Four identical blots (reduced 6%  SDS-PAGE) with purified 
epiglycanin  (E) and proteins of a TA31Ha cell lysate (T), probed with the anti-epiglycanin  antibodies C21, C25, A23, and A27. (B) Immuno- 
precipitation. Antigens were precipitated from 12SI-surface-labeled  TA3/Ha cells (reduced 6% SDS-PAGE). (C) Capping capacity. Cell 
surface distribution of epiglycanin after incubation of TA3/Ha cells with the anti-epiglycanin mAb C21  (left)  and A23  (right) at 200C 
for 45 min. Hereafter cells were fixed in 2% paraformaldehyde in PBS and incubated with FITC-conjugated secondary antibodies, and 
viewed with a confocal laser scanning microscope. The majority of epiglycanin  molecules is capped by C21 (left), but not by A23 (right). 
(D) Epitope. Cell surface expression of anti-epiglycanin  mAb epitopes after treatment of TA3/Ha cells with neuraminidase, O-glycosidase, 
or a combination of both, examined by FACScan  °. The epitope of the capping mAb C21 is susceptible to the digestions, but not that of 
the noncapping mAb A23. Bar, 4.4/~m. 
Neuraminidase was purchased from Sigma. To 2  x  106 cells in 30/~1 
DME 8/~1 neurarninidase (1 U/ml) was added, and cells were incubated at 
37°C for 30 rain.  O-glycosidase was purchased from Boehringer Mann- 
heim. TA3/Ha cells (2  ×  106 in 20 ~1 DME) were incubated with  1 ~1 
O-glycosidase (0.5 U/ml) at 37°C for 30 min. 
Immunofluorescence 
For immunofluorescence analysis, TA3/Ha cells were allowed to adhere to 
hepatocytes or matrix molecules on glass coverslips. Thecells were fixed 
with 2% paraformaldehyde in PBS for 10 min, permeabilized with 0.5% 
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Figure 2. Effect of O-sialoglycoprotein endopeptidase treatment on 
epiglycanin cell  surface  expression.  After treatment  of TA3/Ha 
cells at 37°C for 45 min, cell surface expression of epiglycanin was 
assessed by FACScan  ®  using the capping mAb C21 and noncapping 
mAb A23. Neither  antibody  detected  any epiglycanin after the 
treatment. Cell surface E-cadherin expression using the DECMA-1 
mAb was used as a control. 
Triton X-100 followed  by an incubation for 10 min in PBS containing 1% 
BSA. All immune  incubations were  performed  at 37°C for 30 nlin, all anti- 
bodies were diluted in PBS containing 1% BSA. The secondary  antibodies 
used were biotinylated and detected with extravidin-FITC  or extravidin- 
TRITC. Actin  was visualized  with rhodamine-eonjugated  phaUoidin. Hepa- 
tocytes were stained overnight  with the lipephilic  fluorescent  probe  Dil (oc- 
tadecylindocarbocyanine;  Molecular  Probes)  and washed  three times before 
addition of TA3/Ha cells. The coverslips  were washed, mounted  with Vec- 
tashield (Vector Laboratories, Burlingame, CA), and viewed with a Bio- 
Pad MRC-600 confocal  laser scanning microscope  (Bio-Rad  Laboratories, 
Hemel Hempstead, UK). To test the capping capacity  of anti-epiglycanin 
mAb, cells were incubated in the presence  of the different  mAb at 20"C for 
45 rain. Hereafter,  the cell suspension was spotted  on coverslips, fixed, and 
further treated as described above. 
Results 
Antibodies That Cap Epiglycanin Are Directed against 
an O-linked Sugar Epitope 
We have attempted to raise mAb blocking the adhesion of 
TA3/Ha cells to hepatocytes, but so far only obtained several 
mAb that enhanced adhesion.  Two of these, C21  and C25, 
reacted with a large cell surface protein. However, we also 
obtained mAb that reacted with the same protein but did not 
enhance adhesion to hepatocytes, e.g., A23 and A27. We es- 
tablished that this protein is the mucin epiglycanin. All four 
mAb reacted on a Western blot with purified epiglycanin (E) 
(Codington et al.,  1979) and with a protein of similar size 
in the TA3/Ha cell lysates (T), as shown in Fig. 1 A. Further- 
more, as shown in Fig. 1 B, all four mAb precipitated a pro- 
tein with an apparent Mr of 550 kD, comparable to that of 
purified epiglycanin, from lysates of surface-iodinated TA3/ 
Ha cells. The faint band of 200 kD is a nonspecific band be- 
cause it was also seen in control precipitations (not shown). 
By immunofluorescence we observed a difference between 
the two types of antibodies: C21  and C25 induced capping 
of the epiglycanin molecules, whereas A23 and A27 did not. 
This is shown for C21 and A23 in Fig. 1 C. It should be noted 
that not all epiglycanin molecules were trapped in the cap, 
resulting in some staining on the remainder of the plasma 
membrane. This efficient cross-linking by C21  and C25, in 
the absence of secondary antibodies, might be explained if 
they were directed against O-linked carbohydrate epitopes, 
which are present in multiple copies within an epiglycanin 
molecule (Codington et al., 1975,  1986; Van den Eijnden et 
al.,  1986).  To test this,  TA3/Ha cells  were  treated  with 
O-glycosidase, neuraminidase or both.  Cells were then in- 
cubated with the anti-epiglycanin antibodies and analyzed 
by FACScan  ~.  Removal of sialic acid residues or O-linked 
sugar moieties completely abolished the reaction with the 
capping mAb C21  and C25,  but not with the non-capping 
mAb A23 and A27, as shown for C21 and A23 in Fig.  1 D. 
This demonstrates that sialic acid-containing O-linked sug- 
ars form part of the epitopes of the capping but not of the 
noncapping mAb. 
Epiglycanin Is Cleaved by the Glycoprotease 
O-Sialoglycoprotein Endopeptidase 
O-sialoglycoprotein endopeptidase specifically cleaves heav- 
ily O-linked glycoproteins like glycophorin-A, CD34, CD43, 
CD44, and CD45 (Sutherland et al., 1992). To test whether 
epiglycanin was also cleaved by the glycoprotease, TA3/Ha 
cells were incubated with the enzyme, and subsequently the 
epiglycanin  expression  was  analyzed by FACScan  ® using 
both capping and noncapping mAb. As can be seen in Fig. 
2, for C21 and A23, neither type of mAb detected any epi- 
glycanin after the treatment showing that epiglycanin was 
completely removed. As a control the cell surface expression 
of E-cadherin was analyzed and found not to be changed 
upon the glycoprotease treatment (Fig.  2). 
Capping or Enzymatic Removal of  Epiglycanin Causes 
Adhesion of TA3/Ha Cells to Laminin and Kalinin and 
Enhances Adhesion to Hepatocytes 
TA3/Ha cells grow as single cells in suspension and do not 
adhere to various extracellular matrix components (Kemper- 
man et al., 1994). This could be explained in part by the low 
levels of/3t-integrins on these cells, which are the main me- 
diators of such interactions (Hemler, 1990;  Hynes,  1992). 
However,  the  cells  do express high  levels of the  integrin 
~d~4 (Kemperman et al.,  1993) which binds to laminin and 
kalinin  (Lee et al.,  1992;  Niessen et al.,  1994).  Yet,  the 
TA3/Ha cells did not adhere to either of these proteins. We 
have found  that this  is due to the presence of the  mucin 
epiglycanin. After removal of epiglycanin from part of the 
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Figure 3. Induction of adhesion by antibodies and O-sialoglycopro- 
tein endopeptidase. (A) Effect of  anti-epiglycanin mAb on TA3/Ha 
adhesion to extracellular matrix molecules. The assay is described 
in Materials and Methods. Preincubation with the mAb was for 30 
min and cells were allowed to adhere for 1 h.  Fibronectin  (FN), 
collagen I (Coll. I), collagen IV (Coll. IV), and laminin (LN) were 
coated at a concentration of  20 #g/ml, kalinin-rich matrix (KN) was 
prepared as described.  Capping mAb C21 and C25 induced adhe- 
sion to kalinin and laminin, whereas the noncapping mAb A23 and 
cell surface by capping with mAb C21 and C25, up to 60% 
of added cells bound to kalinin and laminin,  whereas the 
noncapping anti-epiglycanin mAb did not induce adhesion. 
No binding  to collagen I  and IV and  fibronectin was ob- 
served (Fig. 3 A), probably because the cells express hardly 
any/~]  integrins.  Fab  fragments of C21,  which  bound  to 
TA3/Ha cells to the same extent as whole antibody (Fig.  3 
B), did not cap epiglycanin, and did not induce adhesion to 
kalinin  as  shown  in  Fig.  3  C.  Furthermore,  adhesion  of 
TA3/Ha cells to hepatocytes was enhanced by C21 and C25, 
but not by the noncapping anti-epiglycanin antibodies,  as 
can be seen in Fig. 3 E. Capping of another surface protein, 
CD44,  by incubation  of cells with  rat anti-mouse  CD44 
mAb KM 201 followed by polyclonal anti-rat antibodies did 
not result in adhesion to kalinin, although large CD44 con- 
taining caps were seen by immunofluorescence analysis (not 
shown).  Similarly, secondary antibody-induced capping of 
an as yet unidentified surface antigen,  detected by another 
hamster  anti-TA3/Ha  cells  mAb,  1C8.3,  and  highly  ex- 
pressed  on  TA3/Ha  cells,  d'd  not  induce  adhesion  (not 
shown). 
Enzymatic removal of epiglycanin using O-sialoglycopro- 
tein endopeptidase had the same effect. The treated TA3/Ha 
cells adhered to laminin and kalinin and their adhesion to he- 
patocytes was enhanced, as shown in Fig. 3, D and F; adhe- 
sion to kalinin was increased from virtually zero to 60% of 
added cells. Adhesion to hepatocytes was enhanced from 20 
to 40 % of added cells. 
Antibody-induced Adhesion of TA3/Ha Cells to Kalinin 
Results in an Epithelial Morphology 
Remarkably, the TA3/Ha carcinoma cells, which normally 
grow as single cells in suspension, not only adhered to kali- 
nin upon capping of epiglycanin, but actually formed an epi- 
thelial  monolayer.  As  shown  in  Fig.  4,  most of the  cells 
bound to kalinin in the presence of capping antibodies and 
spread within 2 h, whereas cells added in the absence of anti- 
body  or  the  presence of noncapping  antibodies  remained 
rounded and were easily removed by washing.  After over- 
night incubation in the presence of capping antibodies, the 
cells had formed an epithelial monolayer. To study this epi- 
thelial morphology in more detail, the localization of ot~4, 
epiglycanin, E-cadherin and the hemidesmosome-associated 
protein  HD1  was  examined.  By  immunoprecipitation  we 
showed  previously  that  on  TA3/Ha  cells  the  c~  integrin 
subunit is associated only with t4 and not with ~, (Kemper- 
A27 had no effect. (B) Reaction of  C21 IgG and C21 Fab fragments 
with TA3/Ha cells, assessed by FACScan  e. Both react to the same 
extent. (C) Effect of C21 IgG and C21 Fab fragments on adhesion 
of TA3IHa cells to kalinin-rich matrix, assessed as in A. C21 IgG 
induced adhesion whereas C21  Fab fragments had no effect. (D) 
Effect of enzymatic removal of epiglycanin from the cell surface by 
O-sialoglycoprotein endopeptidase (see Fig. 2) on the adhesion of 
TA3/Ha cells to kalinin. Adhesion was quantitated as described for 
A. (E) Effect of anti-epiglycanin mAb on the adhesion of TA3/Ha 
cells to hepatocytes. (F) Effect of  enzymatic removal of  epiglycanin 
from the cell surface on the adhesion of TA3/Ha cells to hepato- 
cytes.  In E  and  F  two different  representative  experiments  are 
shown. Adhesion of  TA3/Ha ceils to hepatocytes varies between 20 
and 40% of added cells between experiments. 
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glycanin mAb on the morphol- 
ogy of TA3/Ha cells that were 
allowed  to  adhere  to  kalinin. 
TA3/Ha cells were preincubated 
at  20°C  for  30  min with  the 
noncapping  anti--epiglycanin 
mAb A23 or with the capping 
anti-epiglycanin  mAb C21 and 
were then allowed to adhere to 
kalinin.  After  2  h  the  plates 
were washed and incubated for 
another 16 h in the presence of 
the antibodies.  Treatment  with 
C21 led to the formation of an 
epithelial  monolayer,  whereas 
A23  did not induce adhesion. 
Bar, 11.7/~m. 
Figure 5. (,4) Localization of c~6,/34, HD1, and E-cadherin in TA3/Ha cells that had been allowed to adhere for 4 h to kalinin upon treat- 
merit with the capping mAb C21. Hereafter  cells were fixed and probed  with the ot6-specific mAb GoH3,  rabbit polyclonal serum 67 
directed against/34, mAb 121 directed against HD1, and a rabbit polyclonal serum directed against E-cadberin (E-cad).  Coverslips were 
viewed with a CLSM. (B) Immunoprecipitation  of E-cadherin, HD1, and t~d34. Antigens were precipitated  from TA3/Ha cells that had 
been metabolically labeled with [asS]methionine/cysteine, using a rabbit polyclonal serum against E-cadherin, mAb 121 against HD1, or 
mAb GoH3 directed  against or6, and analyzed by 6%  reduced SDS-PAGE. Arrows indicate E-cadherin and the coprecipitated  or,/3, and 
3, catenins.  Bar, 6.4/~m. 
The Journal of Cell Biology, Volume 127. 1994  2076 man  et al.,  1994).  Using  the  mAb  GoH3  against  c~6 we 
showed that adhesion to laminin and kalinin is mediated by 
this c¢6/34. Adhesion to laminin was completely blocked by 
GoH3, whereas adhesion to kalinin was partly blocked (re- 
sult not shown), probably because kalinin is a higher affinity 
substrate for ct6/3~ than laminin as shown previously (Son- 
nenberg et al., 1993). However, we can not exclude the pres- 
ence of an additional kalinin receptor on TA3/Ha cells. To 
study the localization of a6/34, we used polyclonal antibod- 
ies  against  the  cytoplasmic domain of/34 (antiserum 67) 
and the mAb GoH3 against the extracellular domain of ott. 
The  specificity of the  polyclonal serum  for ~4  was  con- 
firmed  by  immunofluorescence  analysis  of  /34-negative 
K562 ~ells and K562 cells transfected with both or6 and 134 
cDNA  (Niessen et al.,  1994)  (result not shown).  As  ex- 
pected, we found c~6 and/34 to be colocalized in structures 
at the  substrate contact sites.  These structures resembled 
hemidesmosomes, i.e., spots close to the substrate that are 
arranged in lines (Fig. 5 A and 6, A and B) (Carter et al., 
1990; Owaribe et al.,  1990; Riddelle et al.,  1991; Hieda et 
al.,  1992; Sonnenberg et al.,  1993). We determined by im- 
munoprecipitation that the hemidesmosome-associated pro- 
tein HD1 (Hieda et al., 1992) was expressed in TA3/Ha cells, 
as can be seen in Fig. 5 B. By immunofluorescence, HD1 was 
found to be localized in the same spots as c~6~4, confirming 
that these are hemidesmosome-like structures (Fig. 5 A). 
The fact that TA3/Ha cells formed an epithelial monolayer 
after anti-epiglycanin antibody-induced adhesion to kalinin, 
indicated that also E-cadherin-mediated intercellular adhe- 
sion  had  occurred.  In  fact,  immunoprecipitation  results 
showed that TA3/Ha cells express E-cadherin. Comparable 
amounts  were precipitated  from  suspended  and  adherent 
cells, showing that intercellular adhesion is not caused by in- 
duction of E-cadherin expression upon adhesion to kalinin. 
Also the other components of the cadherin/catenin complex 
were present in both adherent and suspended cells: in both 
cases a, ~, and -y catenin were coprecipitated with E-cad- 
herin as shown in Fig. 5 B for the suspended cells. In mono- 
layers of TA3/Ha cells on kalinin, E-cadherin was found to 
be mainly localized at the cell-cell contact sites (Fig. 5 A). 
Apparently, the presence of the E-cadherin-catenln complex 
is not sufficient to prevent TA3/Ha cells from growing as sin- 
gle cells in suspension, suggesting that E-cadherin function 
is also impaired by epiglycanin. 
If epiglycanin does hinder both cell-matrix and intercellu- 
lar adhesion, it should be absent from the cell-substrate and 
cell-cell contact sites, and that is in fact what we observed: 
during initial attachment epiglycanin was mainly localized in 
a cap facing away from the substrate, and in smaller amounts 
on other parts of  the membrane, but was absent from the sub- 
strate contact site.  When the TA3/Ha cells had spread and 
had formed cell-cell contacts, epiglycanin was exclusively 
present at  the  apical  plasma  membrane and  absent  from 
both cell-substrate and cell-cell contact sites as shown in 
Fig.  6  C. 
Enzymatic Removal of  Epiglycanin from 
the Cell Surface Results in E-cadherin-mediated 
Cell Aggregation 
Enzymatic removal of epiglycanin from the cell surface in 
the presence of Ca  2+ and Mg  2+ resulted in the formation of 
large  cell  aggregates.  To  study  whether  E-cadherin  was 
involved,  TA3/Ha  cells  were  incubated  with  either  the 
DECMA-1  mAb or polyclonal anti-E-cadherin antibodies 
prior to the  glycoprotease treatment.  Both prevented the 
aggregation showing that it is mediated by E-cadherin, as 
shown in Fig.  7 B  for the mAb.  In line with this finding, 
E-cadherin was found to be concentrated at the cell-cell con- 
tact sites in the aggregates, as shown in Fig.  7 A.  Similar 
large  aggregates  were  not  formed after antibody-induced 
capping. This is probably due to the fact that not all epiglyca- 
nin molecules were capped, even though they did react with 
the capping mAb, as can be seen in Fig.  1 C.  Epiglycanin 
is very heterogeneous with respect to its glycosylation state 
(Codington et al., 1975, 1986; Van den Eijnden et al., 1986). 
It is therefore conceivable that molecules containing fewer 
of  the  repeated  carbohydrate  epitopes  are  capped  less 
efficiently. Our results  shows  that  this  limited amount of 
epiglycanin is sufficient to prevent E-cadherin-mediated cell 
aggregation completely. 
Interaction of TA3/Ha Cells with Hepatocytes Results 
in a Redistribution of  Epiglycanin 
Given the complete prevention of both intercellular and ma- 
trix  adhesion  by  epiglycanin,  it  is  remarkable  that  the 
TA3/Ha cells adhere to hepatocytes at all. We have therefore 
studied the localization of epiglycanin on hepatocyte-bound 
nontreated TA3/Ha cells, and found that it was absent from 
the cell-cell contact sites (Fig. 8), indicating that epiglycanin 
was redistributed away from the interaction site. This redis- 
tribution occurs during the interaction with hepatocytes but 
not during contact with a kalinin-rich matrix. 
Discussion 
We have shown here that the mucin epiglycanin on the mouse 
mammary carcinoma cell line TA3/Ha completely prevents 
both ott/34-mediated adhesion to extracellular matrix com- 
ponents and E-cadherin-mediated intercellular adhesion be- 
tween the TA3/Ha cells. The cells express E-cadherin and 
c~d34 at  sufficient levels  for rapid  aggregation  as  well  as 
adhesion  to  the  txt~4 ligands  laminin  and  kalinin  when 
epiglycanin has been removed, and on kalinin an epithelial 
monolayer is formed including the formation of HDl-con- 
taining hemisdesmosome-like structures. Yet, with epiglyca- 
nin on the surface, the cells do not adhere at all to these 
ligands and remain single cells in suspension. 
Mucins are large rodlike molecules that extend far above 
the cell surface, and contain large amounts of O-linked car- 
bohydrate,  including  a  substantial  number  of negatively 
charged sialic acid residues (Devine and McKenzie, 1992). 
Modulation of adhesion by mucins has been demonstrated 
before, in particular for episialin which is expressed by many 
human carcinomas (Hilkens et al.,  1984;  Zaretsky et al., 
1990), and leukosialin (CD43) which is present on many 
types of leukocytes (Manjunath et al.,  1993). For episialin 
it has been shown that the negative charge is not sufficient 
to cause the anti-adhesive effect. Episialin-expressing ceils 
that had been treated with neuraminidase exhibited only a 
partial  restoration of aggregation,  suggesting  that the ex- 
tended structure of the molecule is as important as the nega- 
tive charge (Ligtenberg et al.,  1992). 
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ctd~4, actin, E-cadherin, and 
epiglycanin in TA3/Ha  cells, 
allowed to adhere for 18 h to 
kalinin upon treatment with 
the capping mAb C21. Cells 
were probed with the ot6-spe- 
cific mAb GoH3 (green in A 
and B), polyclonal antibodies 
directed  against  E-cadherin 
(red in B and C), mAb C21 
directed  against  epiglycanin 
(green in C), and rhodamine- 
conjugated phalloidin  to visu- 
alize actin (red in A). A is a 
section focused  at  the  cell- 
substrate  interface  and paral- 
lel to the substrate.  B and C 
are  sections  from  the  same 
coverslip,  perpendicular  to 
the substrate. Coverslips were 
viewed  with  a  CLSM.  Bar, 
6.4/~m. 
Figure  Z  E-cadherin-medi- 
ated  cell-cell aggregation  af- 
ter treatment of TA3/Ha cells 
with  O-sialoglycoprotein  en- 
dopeptidase  in  PBS.  Cells 
were  stained with polyclonal 
anti-E-cadherin  antibodies 
and viewed with a confocal la- 
ser scanning  microscope. In B 
TA3/Ha  cells  were  prein- 
cubated with the  DECMA-I 
rnAb, which blocks E-cadhe- 
rin-mediated adhesion,  prior 
to the treatment with the gly- 
coprotease.  Bar, 7 ttm. 
Figure  8.  Redistribution  of 
epiglycanin on TA3/Ha  cells 
bound to hepatocytes. TA3/Ha 
cells were  allowed to adhere 
for  1 h to hepatocytes.  Cells 
were fixed, permeabilized and 
probed  with  anti-epiglycanin 
mAb C21  (,4) and A23  (B). 
Hepatocytes were stained with 
the lipophilic probe Dil (red). 
Note that part of the Dil has 
leaked  to  the  TA3/Ha  cells. 
Coverslips were viewed with a CSLM. Shown are sections perpendicular to the substrate.  Virtually no epiglycanin (green) is present at 
the site of interaction between the hepatocytes and the TA3/Ha cells. Hepatocytes  are indicated with a (H), and arrows indicate TA3/Ha 
cells.  Bar, 4.0/~m. 
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significant, they are relatively limited compared to the effect 
of epiglycanin. T cell mutants that had lost expression of the 
mucin leukosialin (CIM3), showed a  less than twofold in- 
crease in adhesion to fibronectin and HIV-1 glycoprotein 120 
(Manjunath et al.,  1993).  Cell lines transfected with the 
cDNA  encoding  episialin  exhibited  reduced  aggregation 
compared to revertants that had lost expression of episialin, 
but episialin did not block aggregation completely (Ligten- 
berg et al., 1992). It is not clear why epiglycanin is so effec- 
tive.  An  obvious  possibility is  that  epiglycanin is  much 
longer, and this may in fact explain the difference with leu- 
kosialin, the length of which is only 45 nm. However, episia- 
lin has approximately the same length as epiglycanin, both 
,x,450 rim, whereas other surface proteins like adhesion mol- 
ecules do not extend further than 30 nm above  the lipid 
bilayer (Calafat, J., and J. Hilkens, personal communication; 
Codington et al., 1979; Becker et al., 1989). Also the overall 
molecular weight and the proportion of carbohydrate of the 
two mucins are roughly comparable. The expression level of 
epiglycanin on TA3/Ha cells is extremely high (4  x  106 
mol/cell,  1% of cell dry weight) (Codington et al.,  1975), 
and this undoubtedly contributes to its effectiveness  in pre- 
venting adhesion. However,  E-cadherin-mediated aggrega- 
tion  was  still  prevented  when  a  large  proportion  of the 
epiglycanin was removed by capping with the C21 and C25 
antibodies. The small amount of epiglycanin, present on the 
remainder of the cell surface after capping, was sufficient to 
prevent E-cadherin function suggesting that the expression 
level is not the only reason for the effective adhesion sup- 
pression by epiglycanin. 
Epiglycanin has not yet been cloned, and it is therefore 
difficult to speculate about possible structural differences 
with episialin. Epiglycanin is not the mouse homologue of 
episialin (Spicer et al., 1991; Vos et al., 1991), as suggested 
by preliminary results obtained by Northern blotting and 
staining  with  polyclonal  anti-mouse  episialin  antibodies 
(Vos, H., and J. Hilkens, personal communication). This is 
in agreement with the earlier observation that the amino acid 
compositions are related but not identical (Codington and 
Haavik,  1992). 
Given the effective adhesion suppression by epiglycanin, 
it is striking that TA3/Ha cells do adhere to hepatocytes, and 
in fact do form metastases in the liver upon intraportal injec- 
tion (Roos et al., 1978), and also in the lungs after injection 
into a  tail vein (Roos,  E., unpublished results).  Although 
removal of epiglycanin resulted in increased adhesion to he- 
patocytes, the level of adhesion of nontreated cells is still 
substantial: although levels of adhesion between 20 and 40% 
of added cells may seem low, it should be noted that the 
"monolayers" are not confluent but consist of cords and is- 
lands  covering  roughly 50%  of the  substrate,  and many 
added cells therefore do not sediment onto a hepatocyte. Our 
results show that during this interaction, epiglycanin is redis- 
tributed to the surface facing away from the hepatocyte. It 
is not immediately obvious how this occurs. Conceivably, it 
is a due to a zipper-like process comparable to what has been 
proposed for phagocytosis (Shaw and Griffin, 1981), and that 
epiglycanin is  simply pushed out of the interaction area. 
However,  this depends on interaction with a cell surface, 
since it does not occur on a kalinin matrix. It should be noted 
that when the TA3/Ha cells had formed a monolayer on kali- 
nin after capping with C21 or C25 mAb, the small amount 
of  epiglycanin that was not capped and prevented aggregation 
in  suspension,  had  also  been  redistributed  to  the  apical 
plasma membrane, away from both cell-substrate and inter- 
cellular contact sites. This suggests that the redistribution is 
comparable to the normal polarization of  epithelial cells, and 
depends upon contacts within an organized monolayer. In 
fact, mucins are located apically in normal epithelial cells, 
but often distributed over the entire cell surface in carci- 
nomas (Zaretsky et al., 1990; Hilkens et al., 1992). The in- 
teraction with kalinin or normal epithelial cells like hepato- 
cytes may induce polarization, in line with observations, 
e.g., at the invasive edge of a lung carcinoma in the lungs 
(Dingemans and Mooi,  1986),  that carcinoma cells regain 
their  epithelial  morphology  in  contact  with  pre-existing 
basement membranes and normal epithelial cells. 
The demonstrated effects of mucins on tumor cell behav- 
ior, and particularly metastasis, are limited to modulation of 
host defense. Cells transfected with episialin are to some ex- 
tent protected against lysis by cytotoxic T-lymphocytes (Van 
de Wiel-van Kemenade et al., 1993). Furthermore, ASGP-1, 
a  mucin present on the rat carcinoma cell line 13762 has 
been suggested to be responsible for the resistance of these 
cells to lysis by normal spleen lymphocytes (Sherblom and 
Moody, 1986). In addition, treatment of the same cells with 
tunicamycin led to a decreased level of ASGP-1 on their cell 
surface, and probably as a result of that to a higher suscepti- 
bility to lysis by natural killer cells (Bharathan et al., 1990; 
Moriarty et al., 1990). Also in this respect epiglycanin is ex- 
traordinarily effective,  since TA3/Ha cells can not only be 
transplanted into allogeneic mice but even into rats (Coding- 
ton et al., 1978; Miller et al., 1982). Whether epiglycanin, 
and mucins in general, influence metastasis by modulation 
of adhesion remains to be determined. However,  it seems 
likely that epiglycanin can contribute to release from pri- 
mary tumors,  especially of E-cadherin-expressing  carci- 
nomas, but demonstration of this effect requires mutation 
and transfection of epiglycanin and therefore awaits cloning 
of its cDNA.  We are currently investigating whether epi- 
glycanin affects the invasion of  bloodborne TA3/Ha cells into 
the liver, by pretreatment with O-sialoglycoprotein endopep- 
tidase, in the absence of divalent cations to prevent aggre- 
gation. It is conceivable, that given the observed redistribu- 
tion of epiglycanin upon contact with hepatocytes, this effect 
will be limited. 
So far, the TA3/Ha cell line is the only one known to ex- 
press epiglycanin, and also in normal tissues it has not been 
detected. In preliminary tests using immunohistology with 
the anti-epiglycanin mAb, we have not seen expression in 
neonatal mouse tissues. Given the very potent anti-adhesive 
effect of the molecule, it is likely to play a role in modulation 
of tissue architecture during development, and it will there- 
fore be of interest to identify its normal site and timing of 
expression. 
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